MedPath

studies on the role of HDAC inhibitors to reverse cisplatin resistance in animal models with ovarian cancer developed using tumor tissue from patients

Not Applicable
Conditions
Health Condition 1: C569- Malignant neoplasm of unspecifiedovary
Registration Number
CTRI/2021/04/033090
Lead Sponsor
Indian Council of Medical Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients who are diagnosed with ovarian cancer posted for debulking surgery

Patients who are diagnosed with ovarian cancer posted for ascetic fluid aspiration

Patients with age group > 18 years

Exclusion Criteria

Patients who have received chemotherapy before surgery

Patients who have received chemotherapy before ascetic fluid aspiration

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath